Assessing Myocardial Viability: Principles and the Role of Echocardiography

  • Agnès PasquetEmail author
  • Bernhard Gerber
  • Jean-Louis J. Vanoverschelde


It is the purpose of this chapter to review the actual understanding of the pathophysiology of chronically dysfunctional but viable myocardium and its implications for detection of myocardial viability using echocardiography but also to discuss the clinical role of myocardial viability at present time.


Echocardiographic imaging Myocardial hibernation Heart failure Myocardial viability 

Suggested Reading

  1. 1.
    Vanoverschelde J-LJ, Wijns W, Depré C, Essamri B, Heyndrickx G, Borgers M, Bol A, Melin JA. Mechanisms of chronic regional postischemic dysfunction in humans: new insights from the study of non-infarcted collateral dependent myocardium. Circulation. 1993;87:1513–23.CrossRefGoogle Scholar
  2. 2.
    Vanoverschelde J-LJ, Wijns W, Borgers M, Heyndrickx G, Depré C, Flameng W, Melin JA. Chronic myocardial hibernation in humans. From bedside to bench. Circulation. 1997;95:1961–71.CrossRefGoogle Scholar
  3. 3.
    Ross J Jr. Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation. Circulation. 1991;83:1076–83.CrossRefGoogle Scholar
  4. 4.
    Canty JR, Fallavollita JA. Resting myocardial flow in hibernating myocardium: validating animal models of human pathophysiology. Am J Physiol. 1999;277:H417–22.PubMedGoogle Scholar
  5. 5.
    Borgers M, Thoné F, Wouters L, Ausma J, Shivalkar B, Flameng W. Structural correlates of regional myocardial dysfunction in patients with critical coronary artery stenosis: chronic hibernation? Cardiovasc Pathol. 1993;2:237–45.CrossRefGoogle Scholar
  6. 6.
    Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease. J Am Coll Cardiol. 1997;30:1451–60.CrossRefGoogle Scholar
  7. 7.
    Selvanayagam JB, Jerosch-Herold M, Porto I, et al. Resting myocardial blood flow is impaired in hibernating myocardium: a magnetic resonance study of quantitative perfusion assessment. Circulation. 2005;112:3289–96.CrossRefGoogle Scholar
  8. 8.
    Rahimtoola SH, Dilsizian V, Kramer Ch M, Marwick TH, Vanoverschelde J-LJ, from picture to practice paradigms. Chronic ischemic left ventricular dysfunction: from pathophysiology to imaging and its integration into clinical practice. JACC Cardiovasc Imaging. 2008;1:536–55.CrossRefGoogle Scholar
  9. 9.
    Bayeva M, Sawicki KT, Bultler J, Gheorghiade M, Ardehali H. Molecular and cellular basis of viable dysfunctional myocardium. Circ Heart Fail. 2014;7:680–91.CrossRefGoogle Scholar
  10. 10.
    Schinkel AFL, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375–410.CrossRefGoogle Scholar
  11. 11.
    Anavekar N, Chareonthaitawee P, Narula J, Gersh B. Revascularization in patients with severe left ventricular dysfunction. Is the assessment of viability still viable? J Am Coll Cardiol. 2016;67:2874–87.CrossRefGoogle Scholar
  12. 12.
    Montant P, Chenot F, Goffinet C, Poncelet A, Vancraeynest D, Pasquet A, Gerber BL, Vanoverschelde J-LJ. Detection and quantification of myocardial scars by contrast-enhanced 3D echocardiography. Circ Cardiovasc Imaging. 2010;3:415–23.CrossRefGoogle Scholar
  13. 13.
    Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a metaanalysis. J Am Coll Cardiol. 2002;39:1151–8.CrossRefGoogle Scholar
  14. 14.
    Cleland JGF, Pennell DJ, Ray SG, CHRISTMAS (Carvedilol Hibernating Reversible Ischaemia Trial: Marker of Success) Investigators, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomized controlled trial. Lancet. 2003;362:14–21.CrossRefGoogle Scholar
  15. 15.
    Beanlands RSB, Nichol G, Huszti E, PARR-2 Investigators, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002–12.CrossRefGoogle Scholar
  16. 16.
    D’Egidio G, Nichol G, Williams KA, PARR-2 Investigators, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. J Am Coll Cardiol Img. 2009;2:1060–8.CrossRefGoogle Scholar
  17. 17.
    Bonow RO, Maurer G, Lee KL, STICH Trial Investigators, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–25.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Agnès Pasquet
    • 1
    • 2
    Email author
  • Bernhard Gerber
    • 1
    • 2
  • Jean-Louis J. Vanoverschelde
    • 1
    • 2
  1. 1.Division of CardiologyCliniques Universitaires St LucBrusselsBelgium
  2. 2.Pole of Cardiovascular Research (CARD), Institut de Recherche Expérimentale et Clinique, Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc Université CathologiqueBrusselsBelgium

Personalised recommendations